S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Bank Accounts: Frozen! (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Modern Day Options Trading For Beginners! (Ad)pixel
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:AKUS

Akouos - AKUS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$13.29
$13.29
50-Day Range
$13.29
$13.29
52-Week Range
$2.32
$13.60
Volume
440 shs
Average Volume
344,411 shs
Market Capitalization
$490.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

AKUS stock logo

About Akouos (NASDAQ:AKUS) Stock

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Receive AKUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.

AKUS Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why
Akouos, Inc. (AKUS) Upgraded to Buy: Here's Why
See More Headlines
Receive AKUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter.

AKUS Company Calendar

Last Earnings
11/12/2021
Today
3/26/2023
Next Earnings (Estimated)
4/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKUS
Fax
N/A
Employees
103
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.50
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
-5.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-86,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.90 per share

Miscellaneous

Free Float
35,163,000
Market Cap
$490.88 million
Optionable
Not Optionable
Beta
-0.55

Key Executives

  • Dr. Emmanuel Simons M.B.A. (Age 39)
    Ph.D., Co- Founder, Pres, CEO & Director
    Comp: $790.72k
  • Dr. Michael John McKenna M.D. (Age 65)
    Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board
    Comp: $539.35k
  • Ms. Jennifer Anne Wellman M.S. (Age 44)
    Chief Operating Officer
    Comp: $568.67k
  • Dr. Luk H. Vandenberghe M.D.
    Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. William F. Sewell Ph.D.
    Founder & Member of Scientific Advisory Board
  • Mr. Richard Smith M.D.
    Founder & Member of Scientific Advisory Board
  • Ms. Sachiyo Minegishi (Age 44)
    CFO, Treasurer, Assistant Sec. & Principal Accounting Officer
  • Ms. Stacy Price
    Chief Technical Officer
  • Dr. Aaron Tward M.D.
    Ph.D., Chief Scientific Officer
  • Dr. Karoline K. Shair
    Sr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.













AKUS Stock - Frequently Asked Questions

Should I buy or sell Akouos stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akouos in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AKUS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKUS, but not buy additional shares or sell existing shares.
View AKUS analyst ratings
or view top-rated stocks.

What is Akouos' stock price forecast for 2023?

3 brokers have issued 12-month target prices for Akouos' stock. Their AKUS share price forecasts range from $12.00 to $13.00. On average, they anticipate the company's share price to reach $12.50 in the next year. This suggests that the stock has a possible downside of 5.9%.
View analysts price targets for AKUS
or view top-rated stocks among Wall Street analysts.

When is Akouos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our AKUS earnings forecast
.

How were Akouos' earnings last quarter?

Akouos, Inc. (NASDAQ:AKUS) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.04.

What other stocks do shareholders of Akouos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akouos investors own include NVIDIA (NVDA), Honeywell International (HON), QUALCOMM (QCOM), Raytheon Technologies (RTX), CVS Health (CVS), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Home Depot (HD), Pfizer (PFE) and Procter & Gamble (PG).

When did Akouos IPO?

(AKUS) raised $124 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager.

What is Akouos' stock symbol?

Akouos trades on the NASDAQ under the ticker symbol "AKUS."

Who are Akouos' major shareholders?

Akouos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Credit Suisse AG (0.04%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

What is Akouos' stock price today?

One share of AKUS stock can currently be purchased for approximately $13.29.

How much money does Akouos make?

Akouos (NASDAQ:AKUS) has a market capitalization of $490.88 million. The company earns $-86,670,000.00 in net income (profit) each year or ($2.62) on an earnings per share basis.

How many employees does Akouos have?

The company employs 103 workers across the globe.

How can I contact Akouos?

Akouos' mailing address is 645 SUMMER STREET SUITE 200, BOSTON MA, 02210. The official website for the company is www.akouos.com. The company can be reached via phone at 857-410-1818 or via email at turiano@sternir.com.

This page (NASDAQ:AKUS) was last updated on 3/27/2023 by MarketBeat.com Staff